2423014-07-5
2423014-07-5
Chemical Structure
Sotrovimab
Synonym(s): VIR-7831; GSK-4182136
- CAS No.: 2423014-07-5
- Molecular Weight:(146.463 kDa)
IUPAC Name: (R,Z)-4-((1R,3aS,7aR,E)-4-((E)-2-((3S,5R)-3,5-bis((tert-butyldimethylsilyl)oxy)-2-methylenecyclohexylidene)ethylidene)-7a-methyloctahydro-1H-inden-1-yl)-1-cyclopropylpent-2-en-1-one
SMILES: [Sotrovimab]
Biological Activity: Sotrovimab (VIR-7831) is a human IgG1κ monoclonal antibody targeting the Sarbecovirus subgenus; it is capable of neutralizing SARS-CoV-2, SARS-CoV-1, and various other coronaviruses. Sotrovimab can be used for research on COVID-19[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Sotrovimab | 96.80% | Sotrovimab (VIR-7831) is a human IgG1κ monoclonal antibody targeting the Sarbecovirus subgenus; it is capable of neutralizing SARS-CoV-2, SARS-CoV-1, and various other coronaviruses. Sotrovimab can be used for research on COVID-19. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Gupta A, et al; COMET-ICE Investigators. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. N Engl J Med. 2021 Nov 18;385(21):1941-1950. [Content Brief]
- [2]. Case JB, et al. Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. Nat Commun. 2022 Jul 2;13(1):3824. [Content Brief]
